Methylation of eNOS in the rat penile corpus cavernosum under different pathological states and its relationship with erectile function
- PMID: 37222247
- DOI: 10.1111/andr.13465
Methylation of eNOS in the rat penile corpus cavernosum under different pathological states and its relationship with erectile function
Abstract
Background: It has been shown that methylation in the promoter region of eNOS can downregulate eNOS expression resulting in the endothelial dysfunction. However, it is unclear whether low androgen levels and type 1 diabetes cause ED by methylating the promoter region of eNOS in the penile corpus cavernosum.
Objective: To clarify the effects of type 1 diabetes and hypo-androgen status on the methylation level of the promoter region of the eNOS gene in penile cavernous tissue and their relationship with the erectile function.
Methods: Fifty-eight eight-week-old male Sprague-Dawley rats were randomly divided into six groups (n = 6): sham operation group, castration group, castration+testosterone (cast+T) group, normoglycemia group, diabetic group, and diabetic+methyltransferase inhibitor (5-aza-dc, 1.5 mg/kg) group. The ICPmax/MAP, serum T, the concentration of nitric oxide (NO), the expression of DNMT1, DNMT3a, DNMT3b, and eNOS, and the methylation level of the eNOS promoter region in penile corpus cavernosum of rat were examined 4 weeks after surgery in the sham-operated group, the castration group, and the castration + testosterone replacement group. Those tests were examined after 6 weeks using of methylation inhibitors in the normoglycemic group, the diabetic group, and the diabetic + methylation inhibitor group.
Results: ICPmax/MAP, DNMT1, DNMT3a, DNMT3b, eNOS, and NO levels were significantly lower in castrated rats than in sham and cast+T rats (P < 0.05). ICPmax/MAP, eNOS, and NO levels were lower, and DNMT1, DNMT3a, and DNMT3b expression levels were significantly increased in the diabetic group compared with the normoglycemic and diabetic+methyltransferase inhibitor groups (P < 0.05). There was no significant difference in the methylation level of the promoter region of eNOS in penile cavernous tissue of castrated rats compared with the sham group or the testosterone replacement group. The methylation level of the promoter region of eNOS in penile cavernous tissue was significantly higher in the diabetic group than in the normoglycemic group and diabetic+methyltransferase inhibitor group (P < 0.05).
Conclusion: Although low androgen status inhibited the level of methyltransferase in rat penile cavernous tissue, did not affect the level of methylation in the promoter region of eNOS. Hyperglycemia inhibits the NO level in the penile cavernous tissue and the erectile function of rats by upregulating the methyltransferase level in the penile cavernous tissue and the methylation level in the promoter region of eNOS. Methylation inhibitors can partly improve the erectile function in type 1 diabetic rats.
Keywords: androgen; diabetes; eNOS; erectile function; methylation.
© 2023 American Society of Andrology and European Academy of Andrology.
Similar articles
-
Low androgen level impairs erectile function of rat by regulating the Ng/CaN/AKT/eNOS pathway in penile corpus cavernosum.Andrology. 2022 Sep;10(6):1189-1196. doi: 10.1111/andr.13202. Epub 2022 Jun 15. Andrology. 2022. PMID: 35678097
-
Effect of hypoandrogenism on expression of transient receptor potential vanilloid channels in rat penile corpus cavernosum and erectile function.J Sex Med. 2023 Aug 25;20(9):1153-1160. doi: 10.1093/jsxmed/qdad093. J Sex Med. 2023. PMID: 37490314
-
Low androgen status inhibits erectile function by upregulating the expression of proteins of mitochondria-associated membranes in rat corpus cavernosum.Andrology. 2022 Jul;10(5):997-1007. doi: 10.1111/andr.13188. Epub 2022 May 1. Andrology. 2022. PMID: 35466583
-
Melatonin prevents deterioration of erectile function in streptozotocin-induced diabetic rats via sirtuin-1 expression.Andrologia. 2020 Oct;52(9):e13639. doi: 10.1111/and.13639. Epub 2020 Jun 1. Andrologia. 2020. PMID: 32478903 Review.
-
Androgens and erectile dysfunction: from androgen deficiency to treatment.Sex Med Rev. 2024 Jun 26;12(3):458-468. doi: 10.1093/sxmrev/qeae030. Sex Med Rev. 2024. PMID: 38719619 Review.
References
REFERENCES
-
- Consensus development conference statement. National Institutes of Health. Impotence. December 7-9, 1992. Int J Impot Res. 1993;5:181-284.
-
- Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84:50-56.
-
- Giuliano F, Droupy S. Erectile dysfunction. Prog Urol. 2013;23:629-637.
-
- Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013;381:153-165.
-
- Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacol. 2013;38:23-38.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous